Mayne Pharma Group Ltd. · ASX:MYX
Mayne Pharma — Shareholder Meeting (November 2026)
24 slides from Mayne Pharma's shareholder meeting presentation, Nov 20, 2026
Slide 1: Cover letter to ASX for AGM presentation
20 November 2026 Manager, Company Announcements ASX Limited For personal use only Level 27 39 Martin Place SYDNEY NSW 2000 Via E-Lodgement Dear Sir/Madam Mayne Pharma Group Limited Please find attached the AGM presentation which contains a business update to be delivered to shareholders at Mayne Pha
Slide 2: Mayne Pharma Annual General Meeting
rsonal use only Mayne Pharma Group Limited Annual General Meeting 10.00am (Melbourne Time) 20 November 2026
Slide 3: Chair
rsonal use only Chair Professor Bruce Robinson
Slide 4: Introduction – Directors and KMP
rsonal use only Introduction – Directors and KMP Prof Bruce Robinson Aaron Gray Griffin Buchanan Chair Chief Executive Officer Chief Financial Officer Ann Custin David Petrie Meghan Rivera Jacob Ma-Weaver Non-Executive Director Non-Executive Director Non-Executive Director Non-Executive Director 3
Slide 5: Agenda
rsonal use only Agenda 1 Chair’s Address 2 Business Update 3 Formal Business 4 Close 4
Slide 6: Chair's Address
rsonal use only Chair’s Address Professor Bruce Robinson
Slide 7: Business Update
rsonal use only Business Update Aaron Gray, Chief Executive Officer
Slide 8: Disclaimer
Disclaimer The information provided is general in nature and is in summary form only. It is not complete and should be read in conjunction with the company’s audited Financial Statements and market rsonal use only disclosures, including the ASX announcement dated 17 November 2026 and the Scheme Impl
Slide 9: FY26 Corporate Highlights
FY26 Corporate Highlights A year of resilience and focus against a backdrop of general operational distraction and disruption rsonal use only Realignment of Women’s Health Sales Force • Refreshed sales and marketing materials • Dedicated menopause and contraception field representation driving deepe
Slide 10: Mayne Pharma in 2026
Mayne Pharma in 2026 Branded Product Sales Now Represent a Significant Proportion (%) of Mayne Pharma’s Net Sales, Driving Margin Expansion rsonal use only FY24 FY25 FY26 32% 68% 21% 79% 17% 83% 68% Branded │ 32% Generic 79% Branded │ 21% Generic 83% Branded │ 17% Generic 56% Gross Margin 61% Gross
Slide 11: FY26 Financial Highlights
FY26 Financial Highlights1 Margin expansion and resilient segment contribution through a year of disruption and reinvestment rsonal use only $383.7m 64.7% $34.2m Revenue Gross margin Underlying EBITDA2 down 6% FY25 Up 4.1% from 60.6% FY25 down 27% from $47.0m FY25 $107.1m $34.5m $80.0m Total direct
Slide 12: 1Q FY27 Financial Results
1Q FY27 Financial Results1 1Q FY27 reflects solid momentum from Women’s Health, offset by a decline in higher margin branded Dermatology sales rsonal use only $95.7m 63% $5.3m Revenue Gross margin Underlying EBITDA2 down 2% from 1Q FY26 down from 67% 1Q FY26 down 52% from 1Q FY26 $23.3m -$2.1m $67.3
Slide 13: 1Q FY27 Operating & Financial Highlights (Segments)
rsonal use only 1Q FY27 Operating & Financial Highlights (Segments) Women’s Health Dermatology/DistributeRx • Policy tailwinds with first US congressional hearing on menopause • gACCUTANE® closed 1Q at ~69% category share; result reflects held; Illinois mandates menopause treatment coverage generic
Slide 14: The Rise of Menopause
The Rise of Menopause Global footprint Key Drivers FY26 Penetration of Category1: ~1% rsonal use only 90 84 Total Prescriptions (TRx, ‘000) 77 80 67 • Regulatory de-risking of the category: FDA announced black boxed-warning 70 61 removal for certain hormone replacement therapies (HRTs) in Nov 2025 6
Slide 15: October 2026 Women's Health Update
October 2026 Women’s Health Update Menopause Products1 Contraception Products1,2 rsonal use only 4 months to October 2026 4 months to October 2026 + 24% + 27% + 13% - 4% 15 October: New Menopause Guidance strongly endorses systemic menopausal hormone therapy as the most effective first-line treatmen
Slide 16: DistributeRx: Prescription Access Made Simple
PRESCRIPTION ACCESS MADE SIMPLE rsonal use only DistributeRx partners with manufacturers, providers, and pharmacies to improve patient access and offer predictable prices • ePharmacy size ~US$252 billion by 2030 (CAGR 17%)1 driven by rising consumer adoption of digital pharmacy and home delivery • D
Slide 17: Legal Overhang Materially Reduced
Legal Overhang Materially Reduced Global footprint ® Key aspect of legacy legal matter closing, IMVEXXY IP secured, Cosette appeal dismissed Legal Matters - Summary Positive Impacts rsonal use only US State Attorneys General – generics SETTLED 28 Sep Lower costs Ongoing legal spend 2026 Resolved for
Slide 18: Sale of Mayne Pharma International to Evaris Pharma
Sale of Mayne Pharma International (MPI) to Evaris Pharma - 6 November1 Sale of MPI completes Mayne Pharma’s transition to a specialty pharmaceutical company 100% focused on the United States rsonal use only $55.5m 0.79x 12.1x Total cash consideration FY26 MPI revenue FY26 MPI direct contribution at
Slide 19: Scheme Implementation Deed with Gedeon Richter
Scheme Implementation Deed with Gedeon Richter – 17 November The Mayne Pharma Board unanimously recommends that shareholders vote in favour of the Scheme¹ rsonal use only Significant premium, paid in cash • A$6.40 per share in cash, valuing Mayne Pharma’s equity at approximately A$604 million • 99.4
Slide 20: About Gedeon Richter
• Hungarian multinational pharmaceutical company, founded in 1901 and headquartered in Budapest; listed on Budapest Stock Exchange • Four business units: Women’s Healthcare (WHC), Neuropsychiatry (CNS), Biotechnology and General Medicines rsonal use only • FY251 total sales of EUR 2.34 billion at 31
Slide 21: Conditions Precedent
Conditions Precedent Regulatory rsonal use only • Foreign Investment Review Board (FIRB) approval • Clearance under the United States Hart-Scott-Rodino (HSR) Antitrust Improvements Act • No other orders or injunctions of a Court or Government Agency that would prevent the Scheme Shareholder and Cour
Slide 22: Material Adverse Change Provisions
Material Adverse Change Provisions No Mayne Pharma Material Adverse Change (MAC) is a condition precedent to the Scheme¹ rsonal use only Definition • A MAC requires a diminution in EBITDA of at least $12 million across the full financial year to 30 June 2027 or $12 million across FY28, measured agai
Slide 23: Indicative Timetable and Next Steps
Indicative Timetable and Next Steps Mayne Pharma shareholders do not need to take any action at this stage rsonal use only Event Expected date First Court Hearing Mid December 2026 Scheme Meeting Late January 2027 Second Court Date March 2027 Effective Date Mid to Late March 2027 Implementation Date
Slide 24: Contacts
Contacts rsonal use only For further information contact: Dr Tom Duthy Investor Relations +61 402 493 727 ir@maynepharma.com Click here to view this Presentation on Investor Hub This presentation has been approved for release by the Board of Mayne Pharma You deserve tomorrow. 23
Mayne Pharma Group — Shareholder Meeting (November 2026) on 6ix